D-Mannose for Health & Longevity - Quick Reference Sheet

D-Mannose for Health & Longevity

Created on 06/14/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A food-derived sugar used mainly as a non-antibiotic option to help prevent and ease recurring bladder infections by coating the bacteria so they cannot stick to the bladder. Evidence is genuinely mixed: early studies were encouraging, but larger recent trials found no clear benefit. Safety is excellent; main downside is mild loose stools. (Full Review)

Protocol

Standard Preventive Dose
2 g once daily
Powder dissolved in water; often continued 6 months or longer
Acute/Symptomatic Dose
1.5–2 g, 2–3× daily
For several days, then settle to once-daily maintenance
Best Time of Day
Evening / before bed
Retains mannose-rich urine overnight; daytime divided dosing an alternative
Time to effect
Prevention
Weeks to months
Assessed over consistent daily use, not immediately
Acute Symptom Relief
Within days
Should not replace evaluation of a worsening infection

Benefits

Contraindications
  • Active infection with systemic signs such as fever or flank pain suggesting kidney involvement
  • Suspected pyelonephritis (fever >38°C, flank pain, or rigors)
  • Infections not caused by mannose-sensitive E. coli
Key Interactions
  • Prescribed antibiotics for active infection (e.g., nitrofurantoin, trimethoprim-sulfamethoxazole)
  • Diabetes (use with glucose awareness)
  • Advanced renal impairment (eGFR <30 mL/min/1.73m²)
  • Poorly controlled diabetes (HbA1c well above target)

Risk & Side Effects

  • High: [risks_high]
  • Medium: Gastrointestinal upset
  • Low: Theoretical effect on blood glucose in diabetes; renal burden with very high doses
  • Speculative: Masking or delaying treatment of serious infection

Monitoring

Marker Target Why
Urine culture (during symptoms) No growth when asymptomatic; E. coli during infection Confirms recurrences are mannose-sensitive E. coli, the only target D-Mannose addresses
Urinalysis (leukocytes, nitrites) Negative for nitrites and leukocyte esterase when well Screens for active infection and tracks symptomatic episodes
eGFR >90 mL/min/1.73m² (≥60 generally adequate) Establishes kidney function given D-Mannose is renally cleared
Fasting glucose / HbA1c Fasting 70–90 mg/dL; HbA1c <5.4% Reassurance in diabetics that a sugar supplement is not affecting control

Cadence: Review at 3 and 6 months of preventive use, then every 6–12 months if continued

Qualitative Assessment

  • Reduced frequency of symptomatic urinary infections compared with the pre-treatment baseline
  • Fewer antibiotic courses required over time
  • Reduction in urinary urgency, frequency, and discomfort during episodes
  • Overall confidence and quality of life related to urinary health